{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:46:26Z","timestamp":1791013586674,"version":"4.1.0"},"reference-count":19,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Chemotherapy"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1179\/joc.2004.16.6.595","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T18:05:32Z","timestamp":1389290732000},"page":"595-598","source":"Crossref","is-referenced-by-count":15,"title":["Dysphonia as an Unusual Toxic Event of Oxaliplatin-Based Chemotherapy"],"prefix":"10.1080","volume":"16","author":[{"given":"M.","family":"Berretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Taibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bearz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"La mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.056"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(89)90004-8"},{"key":"CIT0003","first-page":"52","volume":"1996","author":"Rixe O","year":"1855","journal-title":"Biochem Pharmacol"},{"key":"CIT0004","first-page":"23","volume":"25","author":"Becouarn Y","year":"1998","journal-title":"Semin Oncol"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"Giacchetti S","year":"2000","journal-title":"J Clin Oncol"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"de Gramont A","year":"2000","journal-title":"J Clin Oncol"},{"key":"CIT0007","first-page":"32","volume":"25","author":"Bleiberg H","year":"1998","journal-title":"Semin Oncol"},{"key":"CIT0008","first-page":"214","volume":"33","author":"de Gramont A","year":"1997","journal-title":"Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.428"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001113220210"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Sorbye H, Glimelius B, Berglund A et al. Multicenter phase II study of Nordic fluorouracile and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 1,22 (1): 31-38.","DOI":"10.1200\/JCO.2004.05.188"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2000.12.6.525"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/BF00684890"},{"issue":"209","key":"CIT0014","volume":"14","author":"Brienza S","year":"1995","journal-title":"Oxaliplatin (L-OHP): Global safetyin 682 patients. Proc Am Soc Clin Oncol"},{"key":"CIT0015","doi-asserted-by":"crossref","unstructured":"Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: suppl 15 5-13.","DOI":"10.1016\/S0093-7754(03)00399-3"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10500"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Onc 2002; 29, suppl 15: 11-20.","DOI":"10.1053\/sonc.2002.35524"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin based chemotherapy in advanced colorectal cancer: a random-ized, double-blind, placebo controlled trial. J Clin Oncol 2002; 15,20 (16): 3478-3483.","DOI":"10.1200\/JCO.2002.07.061"},{"key":"CIT0019","first-page":"893","volume":"69","author":"Levi F","year":"1992","journal-title":"A chronopharmaco-logic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorec-tal cancer. Cancer"}],"container-title":["Journal of Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10256018808623883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T04:46:42Z","timestamp":1565066802000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2004.16.6.595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,7,18]]},"published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1179\/joc.2004.16.6.595"],"URL":"https:\/\/doi.org\/10.1179\/joc.2004.16.6.595","relation":{},"ISSN":["1120-009X","1973-9478"],"issn-type":[{"value":"1120-009X","type":"print"},{"value":"1973-9478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}